ReviewJournal of diabetes2025
A Comprehensive Review of Novel Advances in Type 1 Diabetes Mellitus.
Review in Journal of diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Protective effects of medicinal honey against doxorubicin-induced hepatorenal toxicity in rats: A novel grading index (PAD score) based on phenolic content and antioxidant capacity.Metabolism open · 2026Article
- Stress-driven remodeling of antigen presentation and chemokine signaling in pancreatic β-cells: implications for type 1 diabetes.Frontiers in immunology · 2026Review
- Development and validation of an interpretable machine learning model for predicting in-hospital hypoglycemia in adults with type 1 diabetes mellitus: a multicenter retrospective study.Frontiers in endocrinology · 2026Article
- Causal association of type 1 diabetes with pancreatic cancer: a multi-ancestry Mendelian randomization study.Archives of medical science : AMS · 2026Article
- Neoepitopes at the crossroads of immunometabolism: metabolic remodeling of antigen presentation in type 1 diabetes.Frontiers in immunology · 2026Review
- Analysis of body composition characteristics in patients with type 1 diabetes mellitus: a case-control study based on a bioelectrical impedance analyzer.Frontiers in medicine · 2026Article
- (TCRαβCells · 2025Review
- A Comprehensive Review of Novel Advances in Type 1 Diabetes Mellitus.Journal of diabetes · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disorder where the immune system targets and destroys insulin-producing β-cells in the pancreas. It generally emerges during childhood or adolescence, but individuals of any age can be affected. In contrast to Type 2 diabetes mellitus (T2DM) which is often associated with lifestyle factors, T1DM cannot be prevented and necessitates lifelong management. Currently, there is no definitive cure for T1DM, and patients rely on continuous insulin injections for their entire lives. Ongoing developments in insulin treatment, such as insulin pumps, continuous glucose monitoring, and hybrid closed-loop systems, offer promising alternatives. Despite advancements in intensive glycemic control that have reduced the occurrence of microvascular and macrovascular complications, a significant number of T1DM patients still these issues. Extensive research efforts are crucial to achieve early detection, prevent the loss of β-cells, and devise improved treatment strategies to enhance the quality of life and prognosis for those affected. This review explores the most noteworthy and recent advancements in the field of T1DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.